Avadel Pharmaceuticals PLC
NASDAQ:AVDL

Watchlist Manager
Avadel Pharmaceuticals PLC Logo
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Watchlist
Price: 10.42 USD 1.86%
Market Cap: 1B USD
Have any thoughts about
Avadel Pharmaceuticals PLC?
Write Note

Gross Margin
Avadel Pharmaceuticals PLC

91.9%
Current
44%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
91.9%
=
Gross Profit
127m
/
Revenue
138.2m

Gross Margin Across Competitors

Country IE
Market Cap 985.5m USD
Gross Margin
92%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 756.2B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 351.2B USD
Gross Margin
69%
Country US
Market Cap 251.2B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 151.1B USD
Gross Margin
71%
No Stocks Found

Avadel Pharmaceuticals PLC
Glance View

Market Cap
1B USD
Industry
Pharmaceuticals
Economic Moat
None

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

AVDL Intrinsic Value
18.02 USD
Undervaluation 42%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
91.9%
=
Gross Profit
127m
/
Revenue
138.2m
What is the Gross Margin of Avadel Pharmaceuticals PLC?

Based on Avadel Pharmaceuticals PLC's most recent financial statements, the company has Gross Margin of 91.9%.